ArticleJACC. Advances2026
Comparative Strategies to Overcome Diuretic Resistance in Heart Failure: A Network Meta-Analysis.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Personalized Sequential Nephron Blockade for Diuretic Resistance in Acute Decompensated Heart Failure: A Narrative Review for the Cardiorenal Clinician.Journal of personalized medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiuretic resistance complicates decongestion in heart failure (HF). Multiple add-on strategies are used, yet comparative efficacy and safety remain uncertain.
objectivesThe objective of the study was to compare pharmacologic strategies for diuretic resistance in HF using a random-effects network meta-analysis of randomized controlled trials (RCTs).
methodsWe searched PubMed/Embase (January 2000-June 2024) for adult HF RCTs with diuretic resistance. Primary outcomes were 72-h urine output and standardized 72-h weight; secondary outcomes were heart-failure hospitalization and cardiovascular mortality; safety was acute kidney injury (AKI). A random-effects network meta-analysis pooled mean differences (MDs) for urine, standardized MDs (SMDs) for weight, and ORs for binary outcomes. Mortality was also assessed by follow-up-adjusted meta-regression of incidence rate ratios.
resultsNineteen RCTs (n = 9,685) were included. Compared with low-dose loop diuretics, 72-hour urine output increased with tolvaptan (MD: 1,840 mL; 95% CI: 441-3,240) and low-dose loop plus tolvaptan (MD: 1,643 mL; 95% CI: 53-3,234). For 72-hour weight change, hydrochlorothiazide (SMD: 1.33; 95% CI: 0.49-2.18) and tolvaptan (SMD: 0.69; 95% CI: 0.09-1.29) produced the greatest standardized reductions. Dapagliflozin (OR: 0.15; 95% CI: 0.03-0.73) and empagliflozin (OR: 0.19; 95% CI: 0.04-0.94) reduced heart failure hospitalizations. Follow-up-adjusted mortality, expressed as incidence rate ratios, was neutral to favorable but imprecise and consistent in ≤60-day sensitivity analyses. High-dose loop diuretics (OR: 2.27; 95% CI: 1.20-4.30) and hydrochlorothiazide (OR: 4.14; 95% CI: 2.03-8.42) were associated with increased acute kidney injury.
conclusionsIn HF with diuretic resistance, sodium-glucose cotransporter 2 inhibitors may lower rehospitalization with a favorable renal profile, whereas nephron-segment add-ons enhance short-term decongestion but warrant AKI/electrolyte monitoring; rankings are exploratory, and choices should emphasize absolute effects and 95% CIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.